1. Optimizing management of advanced urothelial carcinoma: a review of emerging therapies and biomarker-driven patient selection;Black;Can Urol Assoc J,2020
2. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V.3.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 9, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN=National Comprehensive Cancer Network® (NCCN®).
4. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up;Powles;J Clin Oncol,2023
5. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma;van der Heijden;N Engl J Med,2023